Immunocore Files 8-K on Financials and Operations

Ticker: IMCR · Form: 8-K · Filed: Jan 10, 2025 · CIK: 1671927

Immunocore Holdings PLC 8-K Filing Summary
FieldDetail
CompanyImmunocore Holdings PLC (IMCR)
Form Type8-K
Filed DateJan 10, 2025
Risk Levellow
Pages3
Reading Time4 min
Key Dollar Amounts$820 million
Sentimentneutral

Sentiment: neutral

Topics: financial-condition, operations, disclosure

Related Tickers: IMCR

TL;DR

IMCR filed an 8-K on Jan 10, 2025, covering financials and operations. Check for updates.

AI Summary

Immunocore Holdings plc filed an 8-K on January 10, 2025, to report on its results of operations and financial condition, as well as other events and Regulation FD disclosures. The filing also includes financial statements and exhibits. The company is incorporated in England and Wales and its principal executive offices are located in Oxfordshire, United Kingdom.

Why It Matters

This 8-K filing provides investors with crucial updates on Immunocore's financial performance and operational status, impacting investment decisions.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of financial and operational information, not indicating any immediate or significant new risks.

Key Players & Entities

  • Immunocore Holdings plc (company) — Registrant
  • January 10, 2025 (date) — Date of Report
  • England and Wales (jurisdiction) — State of Incorporation
  • 001-39992 (string) — Commission File Number
  • + 44 1235 438600 (phone_number) — Registrant's telephone number

FAQ

What specific financial results are being reported in this 8-K?

The filing indicates it covers 'Results of Operations and Financial Condition' but does not provide specific figures within the provided text.

What are the key items disclosed in this 8-K filing?

The key items disclosed are Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.

When was this 8-K report filed?

The report was filed on January 10, 2025.

Where is Immunocore Holdings plc's principal executive office located?

The principal executive offices are located at 90 Park Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RY, United Kingdom.

What is the Commission File Number for Immunocore Holdings plc?

The Commission File Number is 001-39992.

Filing Stats: 925 words · 4 min read · ~3 pages · Grade level 10.5 · Accepted 2025-01-10 16:26:10

Key Financial Figures

  • $820 million — of December 31, 2024 were approximately $820 million. The information in this Item 2.02 is

Filing Documents

02

Item 2.02. Results of Operations and Financial Condition. On January 10, 2025, Immunocore Holdings plc (the "Company") announced a preliminary estimate of the amount of its cash and cash equivalents at December 31, 2024. The Company preliminarily estimates that its cash and cash equivalents as of December 31, 2024 were approximately $820 million. The information in this Item 2.02 is preliminary, has not been audited and is subject to change pending completion of the Company's audited financial statements for the year ended December 31, 2024. It is possible that the Company or its independent registered public accounting firm may identify items that require the Company to make adjustments to the amounts included in this Item 2.02, and such changes could be material. Additional information and disclosures would also be required for a more complete understanding of the Company's financial position and results of operations as of December 31, 2024.

01

Item 7.01. Regulation FD Disclosure. On January 10, 2025, the Company issued a press release announcing its strategic priorities for 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. Also on January 10, 2025, the Company updated its corporate presentation to reflect certain business and strategic updates. The Company intends to use an abbreviated version of the presentation in meetings with analysts, investors and others from time to time, including its presentation by management at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 at 8:15 a.m. PT. A copy of the presentation is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein. The corporate presentation and a webcast of the Company's presentation at the 43rd Annual J.P. Morgan Healthcare Conference will also be available in the "Investors/Media" section of the Company's website at www.immunocore.com. The Company's website and any information contained on the Company's website are not incorporated by reference into this Current Report on Form 8-K. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

01

Item 8.01 Other Events. On January 10, 2025, the Company published an updated pipeline chart of KIMMRAK and its therapeutic candidates in development, which is filed as Exhibit 99.3 to this Current Report on Form 8-K and incorporated by reference herein.

Financial Statements and Exhibits

Financial Statements and Exhibits Exhibit No. Description 99.1 Press Release dated January 10, 2025. 99.2 Corporate Presentation, dated January 2025. 99.3 Pipeline Chart. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUNOCORE HOLDINGS PLC Dated: January 10, 2025 By: /s/ Bahija Jallal, Ph.D. Name: Bahija Jallal, Ph.D. Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.